HEALTH-ECONOMIC ANALYSIS OF IDEGASP CO-FORMULATION (RYZODEG®) COMPARING WITH OTHER INSULIN TREATMENT REGIMENS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Rationale. The incidence of type 2 diabetes mellitus (T2DM) is still growing in Russia. Insulin is used to treat T2DM at the late stage of disease. Combination of ultra-long and rapid insulins is closest to human physiology. IDegAsp co-formulation (Ryzodeg®) is the only one such formulation available. Aim. To perform health-economic analysis of IDegAsp co-formulation comparing with others insulin treatment regimen. Methods. Decision-tree methodology with cost-utility and budget impact analysis (BIA) along with sensitivity analysis were used to assess three different models. As the study was done from healthcare system perspective only direct medical costs (insulin costs, needles costs, costs of self-monitoring blood glucose and hypoglycemia correction) were accounted for. Results. In both models IDegAsp co-formulation utilities (QALY) were higher and total direct medical costs were lower by 7% to 11% comparing to other insulin treatment regimens, leading IDegAsp co-formulation to be a dominant alternative. The share of insulin cost (47%-74%) was the highest among all the accounted costs. BIA showed that the growth of IDegAsp co-formulation market share leads to the diminishing of total direct medical cost by 3,1% in three years. Conclusion. The therapy of T2DM patients with IDegAsp co-formulation is economically reasonable and leads to budget economy.